



# Valid Reports

Ayurcann: Over 300 Kg of THC and CBD inventory available for BULK OIL SALES

## Ayurcann Holdings Corp (AYUR)

Ayurcann is a leading post-harvest solutions provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada.

### Ayurcann Holdings Corp.

Ayurcann Holdings Corp. through its subsidiary, Ayurcann Inc. (Ayurcann), is engaged in providing post-harvest outsourcing solutions to licensed cannabis producers. The Company is focused on providing and creating custom process and pharma grade products for adults. The Company offers end-to-end full outsourcing solutions including extraction and refinement, formulation and packaging, fulfillment, and distribution. Its extraction and refinement include bulk extraction, winterization services and fractional distillation. The Extraction substance can be returned to the client for their own in-house processing, formulation, packing and distribution. The Company provides bulk oil for manufactures and brands. The Company also provides white label manufacturing, which includes formulations, filling, packaging, and branding.



### AYURCANN


Commence Phase II facility expansion

Sales License granted Jan 14, 2021

Launch of XPLORE branded medical products

Distribution for Brand partners


### Cannabis job growth over the past 5 years



The share price fell 19% from January 1, 2022, to January 17, 2022, after reaching \$0.185 (a 25-week high), due to anticipation of increasing interest rates in the United States and the Ukraine crisis. From January 17, 2022, to March 14, 2022, the share price recovered by 20%, matching the US market, and after Mr. Sudman, CEO of Ayurcann, stated that “the company has increased bulk production to 300,000 kilograms per year and can package up to 3 million production products for the medical and recreational markets,” in addition to operational growth and entry into new markets. However, the share price decreased by 19% between March 14, 2022, and March 28, 2022, after the US Federal Reserve announced an aggressive interest rate hike, , but it quickly rebounded 21 percent after Ayurcann released its second-quarter financials, which indicated ongoing strong results in the fourth quarter, as well as the introduction of new SKUs to the market, with distillate-focused products leading the way. Vape brands are Bravo6, Xplor and Oy Vapes, and Her Highness for Intimacy oils as well as the signing of a letter of intent with Tetra Oils Inc. to purchase a 100% stake in Joints and Hustle & Shake Inc. After the US Federal Reserve hiked key interest rates by 25 basis points on April 4, 2022, the share price fell -35% along with the market from April 4, 2022 to May 30, 2022.

Ayurcann has been nominated  
and won 2 industry awards as Top  
Canadian Processors and Top Tolling  
Provider in the Canadian Cannabis.

### Balance sheet >



Ratio	AYUR	Industry
P/E Ratio	25.93	28.14
Gross margin	53.48	41.35
Operating margin	19.27	-19.00
Net Profit margin	3.82	-22.90
Return on Equity	8.83	-117.39
Quick Ratio	1.80	2.66
Current Ratio	3.79	3.91
Total Debt to Equity	6.21	54.83

Mr. Sudman is a business development specialist who brings over 20 years of experience in a range of industries from real estate development to technology and cannabis.






On May 30, 2022, the stock price reached \$0.115 (a 25-week low), and it entered the oversold zone at 30.79 RSI and began to recover, encountering resistance near \$0.130. (current resistance of 23.60 fibonacci ratio). The technical indicators do not show a clear price correction

Key levels of support and resistance based in Fibonacci Retracement. (25 weeks' levels).

Price: \$0.120 | \$0.185 (25-weeks high) | \$0.115 (25-weeks low)

### Analyst rating



## Revenues of \$2.8 million

\$0.130 (First resistance at 23.60% ratio)  
 \$0.140 (Next resistance at 38.20% ratio)  
 \$0.150 (Resistance at 50% ratio)  
 \$0.160 (Strong resistance at 61.80% ratio)

at this time; the stock could retest the 25-week low and then rise up to 18% around \$0.14. (resistance with a ratio of 38.20 percent ).



Ayurcann Holdings Corp. (AYUR) has an exceptional cash flow in comparison to the capital invested. Furthermore, its financial strength rating is positive, indicating that it is unlikely to face financial difficulties. The average earnings per share (NRI) growth rate over the last three years was 46.90 percent per year. The average earnings per share (NRI) growth rate over the last five years was 30.90 percent per year. VALUATION: The share price of Ayurcann Holdings is \$0.1085. Earnings per Share (Diluted) for Ayurcann Holdings for the trailing twelve months (TTM) ended in March 2022 were \$0.01. However, Ayurcann Holdings' current PE Ratio is 18.08. PROFITABILITY: The gross profit of Ayurcann Holdings for the three months ending March 2022 was \$0.46 million. The revenue of Ayurcann Holdings for the three months ending in March 2022 was \$2.18 Mil. Therefore, Ayurcann Holdings's Gross Margin % for the quarter that ended in Mar. 2022 was 21.07%. HEALTH: AYUR has a Quick Ratio of 1.8. Ranked better than 58.86% of 1118 companies in the Drug Manufacturers industry, this indicates that AYUR is financially average and can meet its short-term obligations with ease. Debt-to-Equity ratio of 0.06 ranks higher than 80.90% of the 864 companies in

Balance Sheet (in thousands of dollars)	2021-06-30	2020-09-30	2019-09-30
Assets	6,677	1,128	1,366
Liabilities and stockholders' equity			
Liabilities			
Current Liabilities	1,572	18.273	18.683
Non-current liabilities	356.082	0	0
Total Liabilities	1,928	18.273	18.683
Stockholders' Equity			
Common Stock	5,788	7,936	7,936
Retained Earnings	-2,016	-7,127	-6,890
Total stockholders' equity	4,749	1,110	1,347
Total liabilities and stockholders' equity	6,677	1,128	1,366

#### DISCLAIMER

This is a paid promotion. All information in this report is assumed to be accurate to the best of our ability. we excludes all liability, to the maximum extent permitted by law, for any inaccuracies in the content or for the consequences of your reliance on the content. Investors should consider this report as only a single factor when making an investment decision